Date de publication: 26 novembre 2020
Promoteur – Intermédiaire Financier
The project supports a biotech company to develop a therapeutic solution for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes research and development (R&D) and related expenses.
The proposed transaction will support R&D investments that are required in order to bring a product to the market addressing a high unmet medical need, for the current COVID-19 crisis. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 24 million
Coût total (montant approximatif)
EUR 50 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Signé - 19/10/2020
Clause de non-responsabilité
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).